

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 CFR 1.56, 1.97, and 1.98) SEP 06 2001 PATENT & TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE O I P E JCS				ATTORNEY DOCKET 37522-1002C1	APPLICATION NO. 09/910,461	
				APPLICANT(S) Peter D. Gluckman, et al.		
				FILING DATE July 20, 2001	GROUP 1639 1027	
US PATENT DOCUMENTS						
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)
ML	A1	4,906,614	3/90	Giertz et al.	514/18	6/14/88
FOREIGN PATENT DOCUMENTS						
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)	
ML	*B4	WO 93/02695	2/93	PCT	No	
ML	B5	WO 93/21216	10/93	PCT	No	
ML	*B6	AU-A-52601/86	7/86	AUSTRALIA	No	
OTHER DOCUMENTS						
† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)				
ML	*C5	Sara et al., Neurpactive Products of IGF-1 and IGF-2 Gene Expression in the CNS, <u>Molecular Biology and Physiology of Insulin-like Growth Factors</u> , pages 439-448, edited by Raizade, M.K., and LeRoith, D., Plenum Press, N.Y. 1991.				
ML	*C6	Guan et al., The effects of IGF-1 treatment after hypoxic-ischemic brain injury in adult rats, Journal of Cerebral Blood Flow and Metabolism 13:609-616 (1993).				
EXAMINER'S SIGNATURE B CEE SA				DATE CONSIDERED 4/9/03	RECEIVED SEP 12 2001 TECH CENTER 1600/2900	
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. <i>Include copy of this form in next communication to applicant.</i>						
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 USC 120. 37 CFR 1.98(d).						

O I P E
SEP 10 2002
P A T E N T & T R A D E M A R K
S E R V I C E

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

SEP 12 2002

Sheet ____ of ____

Attorney Docket Number NRNZ-1002US4	TECH CENTER 001200	Application Number 09/806,536
Applicant Owner Gluckman, et al.		
Filing Date 5/24/01	Group Art Unit 1639	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		

U.S. PATENTS

Examiner Initial	Patent Number	Issue Date	First Named Inventor	Class	Subclass	Filing Date
<i>Y</i>	5,804,550	9/8/98	Bourguignon	514	3	—

U.S. PATENT PUBLICATIONS

Examiner Initial	Patent Application Publication Number	Publication Date	Applicant


PENDING U.S. PATENT APPLICATIONS

Examiner Initial	Application Number	Filing Date	First Named Inventor	Petition to Expunge? Yes No

B

cel5A

4/9/03



**COPIES OF PAPERS
ORIGINALLY FILED**

RECEIVED

SEP 12 2002

Sheet _____ of _____

FOREIGN PATENT DOCUMENTS

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS						
		TECH CENTER 1600/2900				
Examiner Initial	Document Number	Publication Date	Country	Class	Subclass	Trans-lation Yes No
M	WO 95/17204	6/29/95	—	—	—	
M	WO 98/14202	4/9/98	—	—	—	
M	WO 99/65509	12/23/99	—	—	—	
EP	EP 0/366638	5/2/90	—	—	—	

OTHER DOCUMENTS (Include author (if any), title, publisher and place of publication, date and pertinent pages)

Sara, V. R. et al.: "The Biological Role of Truncated Insulin-Like Growth Factor-1 and The Tripeptide GPE In The Central Nervous System", Annals of the New York Academy of Sciences, Vol. 692, pp. 183-191, (1991).

Examiner B CECUS A

Date Considered 4/9/03

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*1 = Copy not submitted because it was submitted in prior application SN 10/631,201, filed 12/15/2008, relied on under 35 USC §120.

*2 = Copy not submitted because it was submitted in prior application SN / filed 20 relied on under 35 USC §120.